» Articles » PMID: 30165518

Intramyocardial Haemorrhage and Prognosis After ST-elevation Myocardial Infarction

Abstract

Aims: To evaluate the prognostic value of intramyocardial haemorrhage (IMH) depicted by T2* imaging for risk stratification in ST-elevation myocardial infarction (STEMI) patients in comparison with established cardiac magnetic resonance (CMR) prognosis markers.

Methods And Results: This multicentre study enrolled 264 patients reperfused within 12 h after symptom onset. CMR was performed within the first week after STEMI to assess left ventricular function and infarct characteristics including IMH. The primary endpoint was a composite of death, reinfarction, and new congestive heart failure (major adverse cardiac events, MACE) at 12 months. MACE occurred in 19 patients (7.2%) showing a higher prevalence of IMH when compared with patients without MACE (47% vs. 21%, P = 0.008). The presence of IMH (n = 60, 23%) was independently associated with MACE after adjusting for clinical risk factors [hazard ratio 2.7, 95% confidence intervals (CIs) 1.1-6.6; P = 0.032] or other CMR prognosis markers (hazard ratio 3.1, 95% CI 1.2-7.7; P = 0.013). The addition of IMH to a model of prognostic CMR parameters (ejection fraction, infarct size, and microvascular obstruction) led to net reclassification improvement of 0.42 (95% CI 0.11-0.73, P = 0.009).

Conclusion: IMH assessed by T2* imaging may provide prognostic information that is incremental to other CMR markers of infarct severity and classical clinical risk factors. IMH could therefore be relevant as an important prognostic measure as well as therapeutic target when caring for patients after STEMI.

Citing Articles

Accurate Intramyocardial Hemorrhage Assessment with Fast, Free-running, Cardiac Quantitative Susceptibility Mapping.

Huang Y, Guan X, Zhang X, Yoosefian G, Ho H, Huang L Radiol Cardiothorac Imaging. 2024; 6(6):e230376.

PMID: 39665631 PMC: 11683678. DOI: 10.1148/ryct.230376.


Rationale and design of the STOP-IMH randomised trial: Safety of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction and the effect on intramyocardial haemorrhage.

Woelders E, Yosofi B, Peeters D, Konijnenberg L, von Birgelen C, van Rees J Int J Cardiol Heart Vasc. 2024; 56:101564.

PMID: 39650751 PMC: 11621486. DOI: 10.1016/j.ijcha.2024.101564.


Impact of Intramyocardial Hemorrhage on Clinical Outcomes in ST-Elevation Myocardial Infarction: A Systematic Review and Meta-analysis.

Vyas R, Changal K, Bhuta S, Pasadyn V, Katterle K, Niedoba M J Soc Cardiovasc Angiogr Interv. 2024; 1(6):100444.

PMID: 39132339 PMC: 11307811. DOI: 10.1016/j.jscai.2022.100444.


Regulatory T Cell as Predictor of Intramyocardial Hemorrhage in STEMI Patients after Primary PCI.

Zhang Y, Gao H, Liu L, Li S, Hua B, Lan D Rev Cardiovasc Med. 2024; 24(7):205.

PMID: 39077002 PMC: 11266489. DOI: 10.31083/j.rcm2407205.


Long-Term Prognostic Value of Infarct Transmurality Determined by Contrast-Enhanced Cardiac Magnetic Resonance after ST-Segment Elevation Myocardial Infarction.

Choi I, Kim H, Gim D, Ki Y, Kim H, Kim S Chonnam Med J. 2024; 60(2):120-128.

PMID: 38841612 PMC: 11148306. DOI: 10.4068/cmj.2024.60.2.120.